Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 8/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
| ▸ | PRF1 | P14222 | 1/20 | 0.35 |
| ▸ | PFKFB4 | Q16877 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724654 | 0.93 | MAPK10 (0.43) | MAPK10MAPK14PFKFB3PRF1PFKFB4 | |
| SCHEMBL6716554 | 0.92 | MAPK10 (0.39) | MAPK10MAPK14PFKFB3PFKFB4MAPK9 | |
| SCHEMBL7210276 | 0.90 | MAPK10 (0.40) | MAPK10PRF1LMNATP53MAPT | |
| SCHEMBL6718112 | 0.86 | MAPK10 (0.40) | MAPK10MAPK14PFKFB3PRF1PFKFB4 | |
| SCHEMBL6718350 | 0.86 | MAPK10 (0.40) | MAPK10MAPK14PFKFB3PFKFB4MAPK9 | |
| SCHEMBL7210365 | 0.82 | MAPK10 (0.42) | MAPK10MAPK14PRF1TP53MAPT | |
| SCHEMBL6717907 | 0.82 | PFKFB3 (0.55) | MAPK10MAPK14PFKFB3PRF1MAPK9 | |
| SCHEMBL6718368 | 0.80 | LMNA (0.51) | MAPK10PFKFB3PRF1USP2LMNA | |
| SCHEMBL6718292 | 0.79 | MAPK10 (0.42) | MAPK10MAPK14PFKFB3PRF1PFKFB4 | |
| SCHEMBL6721167 | 0.79 | CA1 (0.36) | MAPK10MAPK14PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337515-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040450-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | MAPK10 1836/4885MAPK14 2713/4885PFKFB3 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.